SLC39A6 and breast carcinoma: Utilizing the characteristics of the zinc SLC39A6 transporter widely expressed in all breast cancer subtypes, Seattle Genetics has designed and constructed a new antibody–drug conjugate called SGN-LIV1A to treat metastatic breast cancer through the targeted regulation of SLC39A6 (Sun et al., 2011).